BIO-TECHNE Corp (TECH) stock
Close on Nov 11, 2026Market cap $11.42BP/E 66.8Yield 0.44%
BIO-TECHNE Corp grew revenue 0.9% to $1.23B over the twelve months to Sep 30, 2026. Operating income rose 119.1% to $240.84M, moving the operating margin from 9.0% to 19.6%. Free cash flow was $308.20M, up 37.6% from a year earlier. At the latest close the market valued the company at $11.42B, 66.8 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $11.42B
- P/E ratio
- 66.8
- Price to sales
- 9.30
- Price to book
- 5.27
- Dividend yield
- 0.44%
- Free cash flow yield
- 2.70%
Fundamentals
- Revenue
- $1.23B
- EPS, diluted
- $1.09
- Free cash flow
- $308.20M
- Book value per share
- $13.71
- Diluted shares
- 158M
Trading
- Next earnings
- Q1 FY2027, expected soon
- Previous close
- $72.82
- Open
- $72.83
- Day's range
- $72.73 – $72.83
- Volume
- 2,606,697
- Average volume (20 days)
- 2,942,933
- Index membership
- S&P 500 (since Sep 2021), Russell 1000, Russell 3000
- Beta (5 years)
- 1.07
- 52-week range
- $43.20 – $72.88
- RSI (14 days)
- 61.1
- Volatility (1 year)
- 42.9%
- Relative volume
- 0.84×
- WACC
- 10.1%
On 1 of our idea list: Superinvestor favorites
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | TECH | S&P 500 | Difference | TECH per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +0.5% | -2.4% | +2.9 pts | ||
| 3 months | +1.0% | -1.2% | +2.2 pts | ||
| Year to date | +24.3% | +12.3% | +12.0 pts | ||
| 1 year | +23.7% | +12.4% | +11.3 pts | ||
| 3 years | +28.5% | +78.8% | −50.4 pts | +8.7% | +21.4% |
| 5 years | -41.2% | +75.2% | −116.4 pts | -10.1% | +11.9% |
| 10 years | +189.2% | +311.1% | −121.9 pts | +11.2% | +15.2% |
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Bio-Techne filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Results
- Results
- Update
- Results
About Bio-Techne
Biological Products, (No Diagnostic Substances)
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and analytical services across research, diagnostic, and bioprocessing markets. Operating through its Protein Sciences and Diagnostics and Spatial Biology segments, the company offers specialized proteins, antibodies, small molecules, manual and automated protein analysis tools, spatial genomic assays, and clinical diagnostic controls and calibrators. Its products serve academic and industrial researchers, pharmaceutical and biotechnology companies, contract research organizations, diagnostic developers, and clinical testing laboratories worldwide.
Company profile, executives and historyBio-Techne stock: common questions
What is Bio-Techne's stock price?
TECH closed at $72.80 on Nov 11, 2026, down 0.03% on the day. Over the past 52 weeks it traded between $43.20 and $72.88.
What is Bio-Techne's market cap?
Bio-Techne was worth $11.42B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is TECH's P/E ratio?
TECH trades at 66.8 times earnings, based on diluted earnings per share of $1.09 over the twelve months to Sep 30, 2026.
How much revenue does Bio-Techne make?
Bio-Techne reported revenue of $1.23B for the twelve months to Sep 30, 2026, up 0.9% from a year earlier.
Does Bio-Techne pay a dividend?
Yes. Bio-Techne paid $0.32 per share over the last twelve months, a yield of 0.44% at the latest price.
When does Bio-Techne report earnings next?
Bio-Techne's Q1 FY2027 results are due soon; the company has not yet filed them with the SEC.
How has TECH stock performed over the past year?
Including dividends, TECH returned +23.7% over the past year, against +12.4% for the S&P 500.
How many TECH shares are sold short?
8M shares were sold short at the latest FINRA report, 4.93% of the float, or 2.7 days of average trading volume.
Who are Bio-Techne's competitors?
Companies most similar to Bio-Techne by business, industry and size include RGEN, QGEN, ALVO, TWST, QDEL.
See a number that looks wrong?